期刊文献+

Association of CT perfusion imaging with plasma levels of TGF-β1 and VEGF in patients with NSCLC 被引量:3

Association of CT perfusion imaging with plasma levels of TGF-β1 and VEGF in patients with NSCLC
下载PDF
导出
摘要 Objective: To study the association of CT perfusion imaging parameters with plasma level of transforming growth factor-β1(TGF-β1) and vascular endothelial growth(VEGF) in patients with non small cell cancer(NSCLC). Methods: A total of 67 patients with NSCLC(NSCLC group) and 64 patients with benign lesion(control group) were given with CT perfusion imaging to obtain blood flow, blood volume, mean transit time, time to peal and permeability surface through CT perfusion software. The plasma levels of TGF-β1 and VEGF were tested by ELISA. The relationship between plasma levels of TGF-β1, VEGF and CT perfusion imaging parameters were analyzed. Results: CT perfusion imaging parameters and the plasma levels of TGF-β1 and VEGF of NSCLC group were significantly higher than the control group(P<0.05), while CT perfusion parameters and the levels of TGF-β1 and VEGF in NSCLC group showed significant difference in different tumor node metastasis stages(P<0.05). Correlation analysis showed that the level of plasma TGF-β1 and VEGF were positively correlated with blood flow, blood volume, and mean transit time(P<0.05), and negatively correlated with time to peal(P<0.05). There was no significant correlation between TGF-β1 and VEGF with the permeability surface. Conclusions: CT perfusion imaging parameters in patients with NSCLC is closely associated with plasma TGF-β1, VEGF and its biological characteristics. CT perfusion imaging is a convenient method to detect tumor blood perfusion. Objective: To study the association of CT perfusion imaging parameters with plasma level of transforming growth factor-β1(TGF-β1) and vascular endothelial growth(VEGF) in patients with non small cell cancer(NSCLC). Methods: A total of 67 patients with NSCLC(NSCLC group) and 64 patients with benign lesion(control group) were given with CT perfusion imaging to obtain blood flow, blood volume, mean transit time, time to peal and permeability surface through CT perfusion software. The plasma levels of TGF-β1 and VEGF were tested by ELISA. The relationship between plasma levels of TGF-β1, VEGF and CT perfusion imaging parameters were analyzed. Results: CT perfusion imaging parameters and the plasma levels of TGF-β1 and VEGF of NSCLC group were significantly higher than the control group(P<0.05), while CT perfusion parameters and the levels of TGF-β1 and VEGF in NSCLC group showed significant difference in different tumor node metastasis stages(P<0.05). Correlation analysis showed that the level of plasma TGF-β1 and VEGF were positively correlated with blood flow, blood volume, and mean transit time(P<0.05), and negatively correlated with time to peal(P<0.05). There was no significant correlation between TGF-β1 and VEGF with the permeability surface. Conclusions: CT perfusion imaging parameters in patients with NSCLC is closely associated with plasma TGF-β1, VEGF and its biological characteristics. CT perfusion imaging is a convenient method to detect tumor blood perfusion.
机构地区 Radiology Department
出处 《Asian Pacific Journal of Tropical Medicine》 SCIE CAS 2016年第2期175-177,共3页 亚太热带医药杂志(英文版)
关键词 Non small cell LUNG cancer CT PERFUSION parameters TRANSFORMING GROWTH factor-β1 VASCULAR ENDOTHELIAL GROWTH Non small cell lung cancer CT perfusion parameters Transforming growth factor-β1 Vascular endothelial growth
  • 相关文献

参考文献10

  • 1Das M,Wakelee H.Angiogenesis and lung cancer ramucirumab prolongs survival in 2 (nd)-line metastatic NSCLC. Transl Lung Cancer Res . 2014
  • 2Smith NR,Wedge SR,Pommier A,et al.Mechanisms that influence tumour response to VEGF-pathway inhibitors. Biochemical Society Transactions . 2014
  • 3Ryzhov SV,Pickup MW,Chytil A,et al.Role of TGF-βsignaling in generation of CD39+CD73+myeloid cells in tumors. J Immunol . 2014
  • 4Lee JE,Kim C,Yang H,Park I,Oh N,Hua S.Novel glycosylated VEGF decoy receptor fusion protein,VEGF-Grab,efficiently suppresses tumor angiogenesis and progression. Molecular Cancer Therapeutics . 2015
  • 5Gesine Knobloch,Gregor Jost,Alexander Huppertz,Bernd Hamm,Hubertus Pietsch.??Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT(J)European Radiology . 2014 (8)
  • 6Kim J W,Koh Y,Kim D W,et al.Clinical implications of VEGF,TGF-β1,and IL-1βin patients with advanced non-small cell lung cancer. Cancer Res Treat . 2013
  • 7Engels EA,Jennings L,Kemp TJ,Chaturvedi AK,Pinto LA,Pfeiffer RM,et al.Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients. Cancer Med . 2015
  • 8Michalis Alevizakos,Serafim Kaltsas,Konstantinos N. Syrigos.The VEGF pathway in lung cancer[J]. Cancer Chemotherapy and Pharmacology . 2013 (6)
  • 9Nunzia Tacelli,Teresa Santangelo,Arnaud Scherpereel,Alain Duhamel,Valérie Deken,Ernst Klotz,Alexis Cortot,Jean-Jacques Lafitte,Frédéric Wallyn,Jacques Remy,Martine Remy-Jardin.??Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy(J)European Radiology . 2013 (8)
  • 10Reshu Saini,Kenneth Hoyt.??Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis(J)Imaging in Medicine . 2014 (1)

共引文献2

同被引文献20

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部